DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

First Healthcare Compliance, a division of Panacea Healthcare Solutions, and Med USA will co-host a complimentary live webinar, "Compliance Cliffs: Navigating the End of Telehealth Waivers and ...

EMQ, the world's leading provider of open-source MQTT messaging and IoT data infrastructure, today announced the Preview launch of EMQX Tables, a fully managed time-series database natively integrated ...

About 400 participants are expected to participate in the ''4th National Spice Conference'' to be held in the ''chilly city'' Guntur in Andhra Pradesh on November 14-15, informed World Spice ...

Totipotent Cells: Often regarded as the "holy grail" of stem cell biology, these cells can develop into any type of cell in the body, offering vast possibilities for tissue regeneration.

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

The pre-Budget speech by Chancellor Rachel Reeves was a scary listen, not in terms of what was said but the whopping elephant ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

On Tuesday, Metsera announced that Novo Nordisk's new proposal values the company at up to $86.20 per share, amounting to approximately $10 billion. This offer represents a staggering 159% premium ...

Qure (QURE) shares have taken a hit after the FDA withdrew support for using Phase I/II data from its AMT-130 Huntington's disease gene therapy in a key regulatory submission. This unexpected shift ...